14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
SCYX vs AQST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Aquestive Therapeutics, Inc. (AQST) is the stronger overall head-to-head candidate over SCYNEXIS, Inc. (SCYX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SCYX carries a Unified Composite Score of 42.2/100 (HOLD) at $2.38 (1.9x Forward P/E, -126.9% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin).
Technical & Structure Timing Caution: SCYX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.2); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $465.7M market capitalization and -114.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SCYX vs AQST Key Questions & Quantitative Answers
As of Nov 20, 2026, Aquestive Therapeutics, Inc. (AQST) is the stronger overall head-to-head candidate over SCYNEXIS, Inc. (SCYX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SCYX carries a Unified Composite Score of 42.2/100 (HOLD) at $2.38 (1.9x Forward P/E, -126.9% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin). Technical & Structure Timing Caution: SCYX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.2); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AQST leads the Growth & Scale pillar: SCYX posts -82.8% YoY revenue growth and +0.0% YoY earnings growth on $19M TTM revenue (100.0% gross margin, -126.9% operating margin), compared with AQST at -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SCYX cumulative revenue shifted +100.0% while AQST shifted -42.9%. In operating R&D and SG&A reinvestment, SCYX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AQST.
SCYX screens cheaper on headline valuation multiples. SCYX trades at 1.9x Forward P/E, 1.9x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (-63.8% FCF margin), whereas AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SCYX (-21.2% ROE) versus AQST (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, SCYX carries 47.2% implied volatility (4th %ile, Compressed (<25th %ile)), a 20.50x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 73% Vol realized risk). By comparison, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.